• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $RDNT alert in real time by email

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncology Holdings, Inc., which at the time was one of the nation's leading radiation and medical oncology companies.

    "We are very pleased to have a seasoned public company CFO like Mark join our board," said Anne McGeorge, Chairman of the Board of The Oncology Institute. "Mark brings tremendous experience in capital markets, fundraising strategies, strategic financial planning and payor strategy that will be invaluable to TOI in our next phase of growth."

    "I am very excited to join The Oncology Institute's Board of Directors," commented Mr. Stolper. "The Company's mission to provide leading-edge, cost-effective cancer care to improve outcomes and streamline the patient journey is critically important at this time in healthcare. I truly believe that TOI is poised for continued growth and profitability in the coming years."

    About The Oncology Institute

    Founded in 2007, The Oncology Institute (NASDAQ:TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com

    Contacts

    Media

    The Oncology Institute, Inc.

    [email protected]

    Investors

    ICR Healthcare

    [email protected]



    Primary Logo

    Get the next $RDNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDNT
    $TOI

    CompanyDatePrice TargetRatingAnalyst
    RadNet Inc.
    $RDNT
    1/9/2026$92.00Overweight
    KeyBanc Capital Markets
    The Oncology Institute Inc.
    $TOI
    11/25/2025$5.00Buy
    Needham
    The Oncology Institute Inc.
    $TOI
    7/23/2025$8.00Outperform
    Noble Capital Markets
    The Oncology Institute Inc.
    $TOI
    7/16/2025$6.00Buy
    B. Riley Securities
    RadNet Inc.
    $RDNT
    6/13/2025$69.00Buy
    B. Riley Securities
    The Oncology Institute Inc.
    $TOI
    5/15/2025$7.00Buy
    BTIG Research
    RadNet Inc.
    $RDNT
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    RadNet Inc.
    $RDNT
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $RDNT
    $TOI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hively Brad bought $47,168 worth of shares (45,280 units at $1.04), increasing direct ownership by 7% to 712,033 units (SEC Form 4)

    4/A - Oncology Institute, Inc. (0001799191) (Issuer)

    4/28/25 7:20:14 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Virnich Daniel bought $23,584 worth of shares (22,640 units at $1.04), increasing direct ownership by 3% to 724,363 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/28/25 5:50:27 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Medical Officer Podnos Yale bought $9,434 worth of shares (9,056 units at $1.04), increasing direct ownership by 13% to 79,049 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/28/25 5:48:39 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $RDNT
    $TOI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care

    DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates ("USNA" or the "Company"), a physician services organization dedicated to transforming community-based neurology care. Through this partnership, USNA will serve neurology practices and their patients across a broad spectrum of neurological indications. Nitin Jain will serve as USNA's Chief Executive Officer and Brad Hively will serve as Chairman and co-founder. Prior to this role, Nitin Jain served as President of Value Based Care for U.S. Renal Care, and Brad Hively served as CEO of The Oncology Institute (

    1/9/26 4:45:26 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Leadership Promotions

    Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) announced today the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. These promotions reinforce TOI's continued focus on leading the way in value-based cancer care through further development of our technology-enabled care delivery platform as well as strengthening our mission-oriented culture supported by strong leadership. Rakesh Panda has more than 25 years of experience across IT, digital transformation, cybersecurity, and enterprise software develo

    1/9/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    RadNet, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference January 14th, 2026

    LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer, Dr. Gregory Sorensen, Executive Vice President and Chief Strategy Officer and Kees Wesdorp, President & CEO of RadNet Digital Health will be presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. PST. A live webcast of RadNet's presentati

    1/9/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    $TOI
    SEC Filings

    View All

    RadNet Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    1/9/26 4:15:25 PM ET
    $RDNT
    Medical Specialities
    Health Care

    The Oncology Institute Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    1/7/26 5:02:33 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    RadNet Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    12/4/25 5:29:49 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    $TOI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on RadNet with a new price target

    KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00

    1/9/26 9:07:04 AM ET
    $RDNT
    Medical Specialities
    Health Care

    Needham initiated coverage on The Oncology Institute with a new price target

    Needham initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $5.00

    11/25/25 8:00:05 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Noble Capital Markets initiated coverage on The Oncology Institute with a new price target

    Noble Capital Markets initiated coverage of The Oncology Institute with a rating of Outperform and set a new price target of $8.00

    7/23/25 9:21:53 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $RDNT
    $TOI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Carter Robert Ross disposed of $895 worth of shares (244 units at $3.67), decreasing direct ownership by 0.10% to 235,125 units (SEC Form 4)

    4/A - Oncology Institute, Inc. (0001799191) (Issuer)

    1/6/26 4:30:02 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Carter Robert Ross sold $879 worth of shares (247 units at $3.56), decreasing direct ownership by 0.10% to 235,122 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    1/5/26 5:04:59 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Director Hively Brad sold $50,291 worth of shares (13,333 units at $3.77), decreasing direct ownership by 2% to 683,721 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    12/16/25 4:30:05 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $RDNT
    $TOI
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    The Oncology Institute Announces Resignation of Board Member Gabe Ling

    CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise. "On behalf of the Board of Directors, I want to thank Gabe for his service during an important chapter in The Oncology Institute's development," said Anne McGeorge, Chairman of the Board. "We appreciate the contributions he made throughout his time on the Board and the valua

    12/1/25 8:30:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Names Kristin England as Chief Administrative Officer

    CERRITOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, announced today that Kristin England has joined the organization as Chief Administrative Officer (CAO), effective July 7, 2025. In this newly established role, England will oversee Enterprise Central Business Operations and Technology Strategy and Enablement across TOI's expanding national footprint. England brings over two decades of leadership experience in healthcare management and operations, most recently serving as a senior executive within McKesson's US Oncology Network. There, she led high-performing teams focus

    7/14/25 4:05:25 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $RDNT
    $TOI
    Financials

    Live finance-specific insights

    View All

    The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

    CERRITOS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended September 30, 2025 and updated its full year 2025 guidance. Recent Operational Highlights Fee-for-service revenue growth of 13% over Q3 2024, driven by continued organic growth performance in Florida and Oregon.Retail Pharmacy and Dispensary set fill records, contributing $75.9 million in revenue and $12.8 million in gross profit in Q3. Signed several new in-network MSO providers in the Florida market and opened our new TOI pharmacy

    11/13/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    RadNet Acquires CIMAR UK, Empowering DeepHealth to Accelerate AI-Powered Imaging, Reporting and Image-Based Screening

    LOS ANGELES and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a US leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today the acquisition of CIMAR UK, a leading provider of cloud-native healthcare image management solutions. CIMAR will be integrated into DeepHealth, RadNet's wholly owned subsidiary and a global leader in AI-powered health informatics, to advance connected imaging-based care. "Imaging and diagnostics sit at the forefront of care, serving as the gateway to treatment and disease management," said Kees Wesdorp, CEO and President of RadNet's Digital Health division, DeepHealt

    11/11/25 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

    Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 51.6% to $24.8 million in the third quarter of 2025 from $16.4 million in the third quarter of 2024Total Company Adjusted EBITDA(1) was $84.9 million in the third quarter of 2025 as compared with $73.7 million in the third quarter of 2024, an increase of 15.2%; Digital Health reportable segment Adjusted EBITDA(1) increased 6.9% to $3.5 million in the third quarter of 2025 from $3.2 million in the third quarter of 2024Total Company Adjusted EBITDA(1) margins increa

    11/9/25 4:10:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    $TOI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care